Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma : Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy
-
Zandberg, Dan P. (University of Pittsburgh Medical Center. Hillman Cancer Center)
;
Algazi, Alain P. (University of California San Francisco Helen Diller Family Comprehensive Cancer Center) ;
Jimeno, Antonio (Division of Medical Oncology. University of Colorado School of Medicine) ;
Good, James S. (Institute of Head and Neck Studies and Education. Queen Elizabeth Hospital) ;
Fayette, Jérôme (Clinical Oncology. Cancer Center Centre Léon Bérard. University of Lyon) ;
Bouganim, Nathaniel (Department of Oncology. McGill University Health Centre) ;
Ready, Neal E. (Duke University Medical Center) ;
Clement, Paul M. (Department of Oncology. Leuven Cancer Institute) ;
Even, Caroline (Institut Gustave Roussy (Villejuif, França)) ;
Jang, Raymond W. (Princess Margaret Cancer Centre. University of Toronto) ;
Wong, Stuart (Division of Hematology Oncology. Medical College of Wisconsin) ;
Keilholz, Ulrich (Charité Comprehensive Cancer Center) ;
Gilbert, Jill (Henry-Joyce Cancer Clinic) ;
Fenton, Moon (The West Cancer Center. University of Tennessee Health Science Center) ;
Braña, Irene (Vall d'Hebron Institut d'Oncologia) ;
Henry, Stephanie (Department of Oncology-Hematology. Radiotherapy. and Nuclear Medicine. CHU UCL Namur) ;
Remenar, Eva (National Institute of Oncology (Országos Onkológiai Intézet)) ;
Papai, Zsuzsanna (State Health. Center Higatian Defanse Forses) ;
Siu, Lillian L. (Princess Margaret Cancer Centre. University of Toronto) ;
Jarkowski, Anthony (AstraZeneca) ;
Armstrong, Jon M. (AstraZeneca) ;
Asubonteng, Kobby (AstraZeneca) ;
Fan, Jean (AstraZeneca) ;
Melillo, Giovanni (AstraZeneca) ;
Mesía, Ricard (Institut d'Investigació Biomèdica de Bellvitge) ;
Universitat Autònoma de Barcelona